Microbot Medical Inc

Microbot Medical Inc has a market capitalization of $124.24 million and a price-to-book ratio of 20.52, indicating a premium valuation relative to its book value. The company holds $2.47 million in cash and equivalents, with no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 5.32, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of -$4.38 million and free cash flow of -$2.46 million, indicating ongoing cash burn.

The company's financial performance shows significant underperformance relative to typical industry metrics. It reported a net loss of $2.47 million and operating loss of $2.51 million, with return on equity (ROE) of -40.71% and return on assets (ROA) of -33.16%. These metrics suggest the company is not generating returns for shareholders or efficiently utilizing its assets. The enterprise value to EBITDA ratio is negative at -48.50, reflecting the company's unprofitable operations.

Microbot Medical Inc operates as a single-segment entity, with no disclosed geographic revenue breakdown. The company's total assets of $7.43 million and total equity of $6.06 million suggest a relatively small asset base, with no material revenue concentration risks identified in the available data.

The company's growth trajectory is uncertain, with no specific revenue growth rates provided in the available data. Analysts have assigned a mean price target of $7.50 and a median price target of $5.50, with three "buy" ratings and no "strong buy" ratings. The absence of positive earnings and the company's ongoing cash burn raise concerns about its ability to sustain operations without additional capital.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and lack of profitability represent operational risks. The risk of dilution remains low, with no recent issuance or shelf registration activity reported in the available data.

Recent events include the publication of the latest financial data, which shows continued losses and cash burn. No material regulatory or litigation events were disclosed in the available data. The company's reliance on external financing to fund operations remains a key risk factor.

Microbot Medical Inc (MBOT.O) has recorded a series of notable new institutional holdings, marking the first analysis for the ticker with no prior basis for delta computation. The most significant addition involves an investor holding 3,329,721 shares valued at approximately $6.66 million as of December 31, 2025. This position represents a weight of roughly 0.0097% in the investor's portfolio, signaling a substantial entry into the company's equity structure. Additional notable additions were detected across multiple reporting periods, further broadening the shareholder base. As of March 31, 2026, several investors initiated positions, including one holding 816,945 shares valued at $1.97 million and another with 309,103 shares worth $0.74 million. Smaller but notable entries during the same period included holdings of 303,569 shares, 78,504 shares, and 50,000 shares, with values ranging from $0.12 million to $0.73 million. An earlier addition was also recorded for the period ending June 30, 2024, where an investor acquired 137,375 shares valued at $0.14 million. These cumulative additions contribute to a current top holder count of 15, indicating growing institutional interest in the medical technology firm. The detection of these changes occurred on June 20, 2026, providing a snapshot of recent capital allocation trends. The significance of these moves lies in the expanding institutional footprint for Microbot Medical, which currently has four analysts covering the stock and no index memberships. With no officers listed in the current dataset, the focus remains on the capital structure and investor sentiment. The influx of new holders suggests that institutional investors are beginning to position themselves in MBOT.O, potentially laying the groundwork for increased market visibility and liquidity.

Operating income −20,6% YoY; Net income −2,1% YoY.

• ▍Operating income −20,6% YoY
• ▍Net income −2,1% YoY
• ▍Free cash flow −3,1% YoY

Operating income −17,0% YoY; Net income −11,3% YoY.

• ▍Operating income −17,0% YoY
• ▍Net income −11,3% YoY
• ▍Free cash flow −12,2% YoY

Operating income −48,3% YoY; Net income −42,0% YoY.

• ▍Operating income −48,3% YoY
• ▍Net income −42,0% YoY
• ▍Free cash flow −42,4% YoY

Operating income -$2.7M.

• ▍Operating income -$2.7M

Operating income -$3.4M.

• ▍Operating income -$3.4M

Operating income -$3.3M.

• ▍Operating income -$3.3M

Operating income -$2.5M.

• ▍Operating income -$2.5M

Operating income −24,1% YoY; Net income −14,8% YoY.

• ▍Operating income −24,1% YoY
• ▍Net income −14,8% YoY
• ▍Free cash flow −15,7% YoY

Operating income −6,0% YoY; Net income −6,5% YoY.

• ▍Operating income −6,0% YoY
• ▍Net income −6,5% YoY
• ▍Free cash flow −6,6% YoY

Operating income +17,4% YoY; Net income +18,4% YoY.

• ▍Operating income +17,4% YoY
• ▍Net income +18,4% YoY
• ▍Free cash flow +18,9% YoY

Operating income −16,9% YoY; Net income −16,4% YoY.

• ▍Operating income −16,9% YoY
• ▍Net income −16,4% YoY
• ▍Free cash flow −16,3% YoY